Management ChangeJun 15, 2026, 07:01 AM
XORTX Therapeutics Appoints Mika Grasso as Co-CEO
AI Summary
XORTX Therapeutics Inc. announced the appointment of Mika Grasso as Co-CEO, focusing on finance and public markets, as part of a corporate restructuring. The company is prioritizing its lead gout program (XRx-026) and its progressive kidney disease program (XRx-008). XORTX is preparing for an NDA submission for XRx-026 following FDA feedback and aims for marketing approval within 18 months.
Key Highlights
- Mika Grasso appointed as Co-CEO, responsible for finance and public markets.
- XORTX Therapeutics Inc. is focused on restructuring, re-initiating drug development, and preparing regulatory filings for its gout program.
- The company is advancing its lead gout program, XRx-026, with a planned new drug application (NDA) submission.
- XORTX is also developing XRx-008 for progressive kidney disease, including ADPKD.
- The company aims to advance its gout program to marketing approval within the next 18 months.
Price Impact
More from XRTX